← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
ORBIMED ADVISORS LLC
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001055951
Purchase history
- Companies traded
- 13
- Purchases · 12M
- 8
- Purchases · 24M
- 13
- Average purchase
- $12.1M
- Median purchase
- $10.0M
- Gross purchase value
- $157.0M
Companies: ADARx Pharmaceuticals, Inc. | Adicet Bio, Inc. | BlossomHill Therapeutics, Inc. | Braveheart Bio, Inc. | Edgewise Therapeutics, Inc. | Electra Therapeutics, Inc. | MBX Biosciences, Inc. | Prelude Therapeutics Inc | Q32 Bio Inc. | Scribe Therapeutics, Inc. | Shattuck Labs, Inc. | Sionna Therapeutics, Inc. | Traws Pharma, Inc.
13 SEC accession(s) · 13 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-30 | ADARx Pharmaceuticals, Inc. | ADRX | Director | 10% Owner | $16.1M | Open filing |
| 2026-09-23 | Electra Therapeutics, Inc. | ETRA | Director | 10% Owner | $20.0M | Open filing |
| 2026-08-12 | BlossomHill Therapeutics, Inc. | BLSM | Director | $10.0M | Open filing |
| 2026-08-11 | Braveheart Bio, Inc. | BRVE | Director | 10% Owner | $34.9M | Open filing |
| 2026-07-29 | Scribe Therapeutics, Inc. | SCTX | Director | $15.0M | Open filing |
| 2026-06-01 | Q32 Bio Inc. | QTTB | Director | 10% Owner | $15.0M | Open filing |
| 2026-04-28 | Traws Pharma, Inc. | TRAW | 10% Owner | $998.2K | Open filing |
| 2026-04-23 | Prelude Therapeutics Inc | PRLD | Director | 10% Owner | $12.5M | Open filing |
| 2025-10-10 | Adicet Bio, Inc. | ACET | 10% Owner | $5.0M | Open filing |
| 2025-09-02 | Shattuck Labs, Inc. | STTK | Director | $5.5M | Open filing |
| 2025-04-04 | Edgewise Therapeutics, Inc. | EWTX | Director | 10% Owner | $10.0M | Open filing |
| 2025-02-19 | MBX Biosciences, Inc. | MBX | Director | 10% Owner | $2.0M | Open filing |
| 2025-02-10 | Sionna Therapeutics, Inc. | SION | Director | $9.9M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 7Developing | 53.8% (7/13) | 71.4% (5/7) | +5.7% | +4.2% | -15.0% |
| 20D | 5Developing | 45.5% (5/11) | 80.0% (4/5) | +16.7% | +24.6% | -6.4% |
| 60D | 2Small Sample | 25.0% (2/8) | 50.0% (1/2) | +11.7% | +11.7% | -14.1% |
| 120D | 1Small Sample | 16.7% (1/6) | 0.0% (0/1) | -35.8% | -35.8% | -35.8% |
Research patterns
- First purchase in 12M
- 8/8
- Large purchase ≥ $100k
- 13/13
- Cluster buying · 15D
- 13/13
- Buying the dip
- 1/2
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.